Recently, two randomized controlled trials (RCTs) demonstrated that tirzepatide, a dual GLP-1/GIP receptor agonists, reduced the AHI and hypoxic burden, and improved sleep-related patient-reported outcomes among individuals with moderate-to-severe OSA [24]
Third-Party Feedback Platforms: this article does not endorse the accuracy of any third-party review platform, and no such platform was used as a source for this piece
Rare but Serious Warnings Pancreatitis, or inflammation of the pancreas Gallbladder issues, including gallstones Severe allergic reactions Vision changes in people with type 2 diabetes Thyroid tumors, including cancer Severe stomach problems Kidney damage from dehydration Low blood sugar in people with type 2 diabetes Increased resting heart rate Food or liquid getting into the lungs during surgery Gastroparesis (stomach paralysis) While rare, these side effects are possible
Compared with DPP4i use, GLP-1RA therapy was associated with a 20% lower risk of overall dementia (hazard ratio [HR] 0.80
Immediate, reliable absorption for patients with oral intolerance or severe need
no convierten cualquier vial con el mismo nombre en el producto usado en esos ensayos